Abstract: A behavior detection system has access to a collection of behavior definitions that each describe a functional behavior of a system. Each behavior definition includes multiple basic operations, each of which includes an identifier and one or more parameters. The behavior definition also includes, explicitly or inherently, a basic operation combination definition that describes a sequence or other manner in which the basic operations are combined. The behavior detection system analyzes events in an event log for the system and determines whether the events in the event log satisfy any of the behavior definitions. An appropriate responsive action is taken in response to detecting that the events in the event log satisfy a behavior definition. The collection of behavior definitions is scalable, allowing behavior definitions to be added or deleted, and allowing basic operations in a behavior definition to be changed (e.g., adding, removing, and/or modifying basic operation parameters).

Abstract: A behavior detection system has access to a collection of behavior definitions that each describe a functional behavior of a system. Each behavior definition includes multiple basic operations, each of which includes an identifier and one or more parameters. The behavior definition also includes, explicitly or inherently, a basic operation combination definition that describes a sequence or other manner in which the basic operations are combined. The behavior detection system analyzes events in an event log for the system and determines whether the events in the event log satisfy any of the behavior definitions. An appropriate responsive action is taken in response to detecting that the events in the event log satisfy a behavior definition. The collection of behavior definitions is scalable, allowing behavior definitions to be added or deleted, and allowing basic operations in a behavior definition to be changed (e.g., adding, removing, and/or modifying basic operation parameters).

Abstract: A behavior detection system has access to a collection of behavior definitions that each describe a functional behavior of a system. Each behavior definition includes multiple basic operations, each of which includes an identifier and one or more parameters. The behavior definition also includes, explicitly or inherently, a basic operation combination definition that describes a sequence or other manner in which the basic operations are combined. The behavior detection system analyzes events in an event log for the system and determines whether the events in the event log satisfy any of the behavior definitions. An appropriate responsive action is taken in response to detecting that the events in the event log satisfy a behavior definition. The collection of behavior definitions is scalable, allowing behavior definitions to be added or deleted, and allowing basic operations in a behavior definition to be changed (e.g., adding, removing, and/or modifying basic operation parameters).

Abstract: A behavior detection system has access to a collection of behavior definitions that each describe a functional behavior of a system. Each behavior definition includes multiple basic operations, each of which includes an identifier and one or more parameters. The behavior definition also includes, explicitly or inherently, a basic operation combination definition that describes a sequence or other manner in which the basic operations are combined. The behavior detection system analyzes events in an event log for the system and determines whether the events in the event log satisfy any of the behavior definitions. An appropriate responsive action is taken in response to detecting that the events in the event log satisfy a behavior definition. The collection of behavior definitions is scalable, allowing behavior definitions to be added or deleted, and allowing basic operations in a behavior definition to be changed (e.g., adding, removing, and/or modifying basic operation parameters).

Abstract: The present invention relates to new pharmaceutically acceptable salts of 2-hydroxy-3-[5-(morpholin-4-yl-methyl)pyridin-2-yl]1H-indole-5-carbonitrile, processes for their preparations, pharmaceutical formulations containing said salts and to the use of said active salts in therapy, and particularly to GSK3 related disorders.

Abstract: The present invention relates to a new use of a compound of the formula (I) wherein R1 is NH2, piperazin-1-yl, 4-methylpiperazin-1-yl, 4-methyl-1,4-diazepan-1-yl or 4-ethylpiperazin-1-yl; R2 is hydrogen, fluoro, CH3, CH2CH3, OCH3, CF3 or OCF3; R3 is hydrogen, CH3 or fluoro; as a free base or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention and/or treatment of bone-related disorders, osteoporosis and increasing bone formation, bone mineral density. The present invention further relates to a method of prevention and/or treatment of these disorders.

Abstract: New use of 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile as a free base or a pharmaceutically acceptable salt thereof, in a method of prevention and/or treatment of bone-related disorders, osteoporosis, increasing bone formation or increasing bone mineral density.

Abstract: The present invention relates to a new use of a compound of the formula (I) wherein R1 is NH2, piperazin-1-yl, 4-methylpiperazin-1-yl,4-methyl-1,4-diazepan-1-yl or 4-ethylpiperazin-1-yl; R2 is hydrogen, fluoro, CH3, CH2CH3, OCH3, CF3 or OCF3; R3 is hydrogen, CH3 or fluoro; as a free base or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention and/or treatment of bone-related disorders, osteoporosis and increasing bone formation, bone mineral density. The present invention further relates to a method of prevention and/or treatment of these disorders.

Abstract: The salt, the 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile citrate, a process for its preparation, pharmaceutical formulations containing it and the use of it in therapy, and particularly in the therapy of GSK3 related conditions and disorders.

Abstract: The present invention relates to a new use of a compound of the formula (I) wherein R1 is NH2, piperazin-1-yl, 4-methylpiperazin-1-yl, 4-methyl-1,4-diazepan-1-yl or 4-ethylpiperazin-1-yl; R2 is hydrogen, fluoro, CH3, CH2CH3, OCH3, CF3 or OCF3; R3 is hydrogen, CH3 or fluoro; as a free base or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention and/or treatment of bone-related disorders, osteoporosis and increasing bone formation, bone mineral density. The present invention further relates to a method of prevention and/or treatment of these disorders.